Maculaser
maculaser.com
Hospitals & Health Systems
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
ZEISS Ventures and M2Care invest in Maculaser to advance temperature-controlled retinal laser therapy
Helsinki, 28 May 2026 ZEISS Ventures has joined Maculaser's latest funding round, co-led together with M2Care. The investment marks the first close of the round, with the full round to be announced shortly. The funding will support Maculaser's progression
Read more
Report
M2care et ZEISS Ventures soutiennent Maculaser Oy pour accélérer le développement d'une thérap
M2Care
Read more
Report
EQS-News: M2Care: M2care and ZEISS Ventures Support Maculaser Oy to Advance Pioneering Temperature-Controlled Retinal Laser Therapy
EQS-News: M2Care / Key word(s): Financing M2care and ZEISS Ventures Support Maculaser Oy to Advance Pioneering Temperature-Controlled Retinal Laser Therapy 28.05.2026 / 09:30
Read more
Report
Nature Communications publishes ERG-guided, temperature-controlled retinal laser study
Researchers at Aalto University, Karolinska Institutet / St. Erik Eye Hospital, and the University of Helsinki demonstrate that real-time electroretinography (ERG)-based thermal dosimetry can activate cytoprotective pathways without retinal damage in a pr
Read more
Report
Maculaser Joins €32M EU-Funded PhotonMed Initiative to Advance Retinal Care with Photonics
We are proud to announce that Maculaser is now part of PhotonMed, a €32 million European Union (Chips Joint Undertaking, Chips JU)-funded initiative spanning 9 countries. This ambitious collaboration brings together leading research institutes and industr
Read more
Report
New Clinical Trial Manager joins Maculaser
We are pleased to announce that Aki Vartiainen joins the Maculaser team as Clinical Trial Manager.Aki brings strong expertise to our team, having worked on over 20 clinical trials, including First-In-Human and post-market studies. With 7 years of experien
Read more
Report
Maculaser secures its first Japanese patent
Maculaser has been granted a Japanese patent for its method and device for determining changes in retinal and/or brain temperature. This is Maculaser's first patent outside the EU and US and marks a significant milestone for the company. The newly granted
Read more
Report
Maculaser's retinal treatment technology exhibited in Media
Finnish new technology focused magazine T&T (Tekniikka ja Talous) reports on Maculaser's goals and timeline in developing novel treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy. (in Finnish, paywall) https:
Read more
Report
New Head of Regulatory Affairs and Quality Assurance joins the team
We are excited to announce that Kirsty Happonen joins the Maculaser team as Head of Regulatory Affairs and Quality Assurance. Kirsty is a Canadian with 10+ years bringing medical devices to market in industries such as dental, imaging and point-of-care di
Read more
Report
General Application
Join Our Team - General Application We are seeking talented professionals to advance our mission of preventing blindness through innovative retinal laser treatments. What We Offer Work towards a meaningful goal: Our mission is to prevent blindness and sig
Read more
Report
Show more news